# Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

> **NCT01719250** · EARLY_PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 7 (actual)

## Conditions studied

- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Transformed Recurrent Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Buparlisib
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT01719250
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2016-09-16
- **Final completion:** 2017-03-22
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2018-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01719250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01719250, "Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01719250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*